FASN and neoplasm: The first-generation FASN inhibitors include C75, orlistat, epigallocatechin gallate (EGCG), and cerulenin, which were initially found to significantly reduce the growth of tumor xenografts, induce cell cycle arrest, and suppress the transcription of oncogenes.